 |
|
|
|
|
Baxter Recalls Rest of Heparin Products
|
| | | | Related Healthscout Videos | |
|
Page: << Prev | 1 | 2 | 3 Rogers noted that while the FDA was concerned about what it found in the Chinese plant, it was not prepared to make a connection between these observations and the adverse events associated with Baxter's heparin.
Inspection of the Chinese plant came after the FDA reported Feb. 19 that it had made a mistake and inspected the wrong Chinese plant, which had a similar name.
More information
Text Continues Below
For more on heparin, visit the U.S. National Library of Medicine.
Page: << Prev | 1 | 2 | 3
|
Copyright © 2008 ScoutNews, LLC. All rights reserved.
Last updated 2/29/2008
|
|
SOURCES: Feb. 28, 2008, teleconference with Rear Admiral Sandra Kweder, M.D., deputy director, Office of New Drugs, Center for Drug Evaluation and Research; Michael Rogers, director, Division of Field Investigations, Office of Regulatory Affairs, U.S. Food and Drug Administration, Rockville, Md.
|
.gif)
